Deterministic models. Sovereign infrastructure. Actionable results.
Unlike purely predictive approaches, Lafame relies on deterministic models and sovereign infrastructure, prioritising understanding, explainability and control over data to produce reliable and directly actionable results.
We offer a service for the genetic optimisation of antiviral vaccines. Our technology identifies the peptides to be selected for a vaccine that allows little or no therapeutic escape.
If you're looking to identify new targets for RNA viruses, AfterVir outlines all the solutions for preserving therapeutic escape.
Technological Core
Shared biological processing engine
Virology
AfterVir Software©AfterVir biological processer
Ready for the market
Core features
Oncology
OncoTwin Software©OncoTwin digital twin
In development
Lafame develops deterministic models based on disciplinary knowledge, thereby avoiding the 'black box' effect of AI. Thanks to 'augmented AI', Anne Vanet's team has created a pioneering software programme which, based on specific studies of proteins involved in a patient's pathology, identifies the mutations or groups of mutations that are harmful to the organism in question, so that they can be counted.
The innovative nature of our technology lies in reversing the trend of viewing the accumulation of mutations not as a failure but as valuable information to develop these models and to 'counter' them. If necessary, AI models can be added to enhance the results.
In virology, our targets and vaccine solutions against RNA virus, are designed to prevent resistance.
In oncology, our targets and working OncoTwin identify patient sub-populations. Finally, Lafame treats cancers via drug-repurposing — a strategy suggested by the Institut Gustave Roussy.